



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Hydroxy Pioglitazone

Item No. 28043

CAS Registry No.: 146062-44-4
Formal Name: 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione
MF: C₁₉H₂₀N₂O₄S
FW: 372.4
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Hydroxy pioglitazone is supplied as a solid. A stock solution may be made by dissolving the hydroxy pioglitazone in the solvent of choice. Hydroxy pioglitazone is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas.

Description

Hydroxy pioglitazone is a major metabolite of the peroxisome proliferator-activated receptor γ (PPAR γ) agonist pioglitazone (Item Nos. 71745 | 22263 | 10028).¹ It is formed from pioglitazone by the cytochrome P450 (CYP) isoform CYP2C8 with minor contributions from CYP3A4.² Hydroxy pioglitazone binds to PPAR γ ($K_i = 1.2 \mu\text{M}$) and activates PPAR γ in a time-resolved FRET (TR-FRET) assay ($\text{EC}_{50} = 2.1 \mu\text{M}$).¹

References

1. Mosure, S.A., Shang, J., Eberhardt, J., *et al.* Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the antidiabetic PPAR γ drug pioglitazone. *J. Med. Chem.* **62**(4), 2008-2023 (2019).
2. Jaakkola, T., Backman, J.T., Neuvonen, M., *et al.* Effect of rifampicin on the pharmacokinetics of pioglitazone. *Br. J. Clin. Pharmacol.* **61**(1), 70-78 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/10/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM